Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18

Journal of Immunotherapy

Volumn 38, Issue 4, 2015, Pages 145-154

  Roeven, Mieke W H ^a   Hobo, Willemijn ^a   Van Der Voort, Robbert ^a   Fredrix, Hanny ^a   Norde, Wieger J ^a   Teijgeler, Kasper ^a   Ruiters, Marcel H J ^b   Schaap, Nicolaas ^a   Dolstra, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Synvolux Therapeutics   (Netherlands)

Author keywords

dendritic cell vaccination; lipoplexes; minor histocompatibility antigens; PD1 ligands; siRNA delivery

Indexed keywords

1 METHYL 4 ( 9 DIOLEYL)METHYLPYRIDINIUM CHLORIDE; ANTIGEN; DENDRITIC CELL VACCINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; LIPOPLEX; MESSENGER RNA; MINOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1-METHYL-4-(9-DIOLEYL)METHYLPYRIDINIUM; CANCER VACCINE; CYTOKINE; PDCD1LG2 PROTEIN, HUMAN; PYRIDINIUM DERIVATIVE;

ANTIGENICITY; ARTICLE; CELL EXPANSION; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG MANUFACTURE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; INSTRUMENT STERILIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; CELL CLONE; CELL PROLIFERATION; CHEMISTRY; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES;

ANTIGENS, CD274; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CLONE CELLS; CYTOKINES; DENDRITIC CELLS; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PYRIDINIUM COMPOUNDS; RNA, SMALL INTERFERING; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84928481634     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000071     Document Type: Article

References (30)

1. Palucka K, Ueno H, Roberts L, et al. Dendritic cells: are they clinically relevant?. Cancer J. 2010; 16: 318-324.
2. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009; 58: 1-14.
3. Draube A, Klein-Gonzalez N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS One. 2011; 6: e18801.
4. McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother. 2003; 52: 583-591.
5. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38-48.
6. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2-5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest. 2005; 115: 3506-3516.
7. Hobo W, Broen K, van der Velden WJ, et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19: 274-282.
8. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol. 2005; 17: 202-210.
9. Overes IM, Fredrix H, Kester MG, et al. Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2-5 mRNA-electroporated dendritic cells. J Immunother. 2009; 32: 539-551.
10. Aarntzen EH, Schreibelt G, Bol K, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res. 2012; 18: 5460-5470.
11. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001; 98: 49-56.
12. Hobo W, Strobbe L, Maas F, et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother. 2013; 62: 1381-1392.
13. Hobo W, Maas F, Adisty N, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood. 2010; 116: 4501-4511.
14. Hobo W, Novobrantseva TI, Fredrix H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. 2013; 62: 285-297.
15. Asgeirsdottir SA, Zwiers PJ, Morselt HW, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol. 2008; 294: F554-F561.
16. van der Woude I, Wagenaar A, Meekel AA, et al. Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery. Proc Natl Acad Sci U S A. 1997; 94: 1160-1165.
17. Geel TM, Meiss G, van der Gun BT, et al. Endonucleases induced TRAIL-insensitive apoptosis in ovarian carcinoma cells. Exp Cell Res. 2009; 315: 2487-2495.
18. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008; 105: 11915-11920.
19. Norde WJ, Overes IM, Maas F, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood. 2009; 113: 2312-2323.
20. Velten FW, Rambow F, Metharom P, et al. Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells. Mol Immunol. 2007; 44: 1544-1550.
21. Ohl L, Mohaupt M, Czeloth N, et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004; 21: 279-288.
22. Seth S, Oberdorfer L, Hyde R, et al. CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions. J Immunol. 2011; 186: 3364-3372.
23. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011; 186: 1325-1331.
24. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
25. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12: 265-277.
26. Lesterhuis WJ, Schreibelt G, Scharenborg NM, et al. Wildtype and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother. 2011; 60: 249-260.
27. Hubo M, Trinschek B, Kryczanowsky F, et al. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol. 2013; 4: 82.
28. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996; 334: 281-285.
29. Spierings E, Kim YH, Hendriks M, et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19: 1244-1253.
30. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000; 6: 1011-1017.